"10.1371_journal.pone.0124845","plos one","2015-08-05T00:00:00Z","Gitanjali M Singh; Renata Micha; Shahab Khatibzadeh; Peilin Shi; Stephen Lim; Kathryn G Andrews; Rebecca E Engell; Majid Ezzati; Dariush Mozaffarian; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE)","Friedman School of Nutrition Science and Health Policy, Tufts University, Boston, MA, United States of America; Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States of America; Institute of Health Metrics and Evaluation, Seattle, WA, United States of America; Department of Global Environmental Health, School of Public Health, Imperial College London, London, United Kingdom; Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece","Conceived and designed the experiments: GMS RM SK PS SL KGA REE ME DM. Analyzed the data: GMS RM SK PS KGA REE. Contributed reagents/materials/analysis tools: GMS RM SK PS KGA REE SL ME DM. Wrote the paper: GMS RM DM.","The authors would like to provide the following disclosures: Dr. Mozaffarian reports research grants from GlaxoSmithKline, Sigma Tau, Pronova, and the National Institutes of Health for a completed investigator-initiated, not-for-profit, randomized clinical trial of fish oil supplements for the prevention of post-surgical complications; ad hoc travel reimbursement and/or honoraria for one-time scientific presentations or reviews on diet and cardiometabolic diseases from Bunge, Pollock Institute, Quaker Oats, and Life Sciences Research Organization (each modest); ad hoc consulting fees from McKinsey Health Systems Institute, Foodminds, and Nutrition Impact (each modest); Unilever North America Scientific Advisory Board membership (modest); and royalties from UpToDate, for an online chapter on fish oil (modest). Harvard University has filed a provisional patent application, that has been assigned to Harvard University, listing Dr. Mozaffarian as a co-inventor to the US Patent and Trademark Office for use of trans-palmitoleic acid to prevent and treat insulin resistance, type 2 diabetes, and related conditions (Patent name: “Use of trans-palmitoleate in identifying and treating metabolic disease”; Patent number: 8,889,739). All other authors declare that they have no conflicts of interest. This information does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","08","Gitanjali M Singh","GMS",10,TRUE,9,NA,6,3,TRUE,TRUE,TRUE,1,"10",TRUE
